Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 17 | 832 | 21% |
| 2020 | 14 | 780 | 25% |
| 2021 | 16 | 761 | 29% |
| 2022 | 17 | 759 | 33% |
| 2023 | 16 | 758 | 37% |
| 2024 | 18 | 814 | 39% |
| 2025 from claims | – | 787 636–924 | 40% |
| 2026 forecast | – | 880 690–1,106 | 35% |
| 2027 forecast | – | 912 676–1,206 | 34% |
| 2028 forecast | – | 945 669–1,305 | 34% |
| 2029 forecast | – | 980 666–1,405 | 33% |
| 2030 forecast | – | 1,015 665–1,506 | 33% |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 76% of the cases CMS names in New Hampshire; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 62% inpatient hospital, 38% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~880 | ~550 | ~330 |
| 2027 · ~910 | ~570 | ~340 |
| 2028 · ~950 | ~600 | ~350 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 37% (38% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 148 | 8,138−3%/yr | −3%/yr | 4.7 | 0% | 8,390 in 2030+0.5%/yr |
| Pennsylvania | 147 | 7,396−2.8%/yr | −2.8%/yr | 5.6 | 2% | 6,810 in 2030−1.4%/yr |
| New Jersey | 86 | 4,680−4.6%/yr | −4.6%/yr | 4.6 | 0% | 4,910 in 2030+0.8%/yr |
| Massachusetts | 90 | 4,351−1.6%/yr | −1.6%/yr | 4.7 | 0% | 4,910 in 2030+2%/yr |
| Connecticut | 40 | 1,648−4.1%/yr | −4.1%/yr | 5.2 | 0% | 1,830 in 2030+1.8%/yr |
| Maine | 16 | 574−6.2%/yr | −6.2%/yr | 3.8 | 0% | 530 in 2030−1.4%/yr |
| Rhode Island | 9 | 460−6.3%/yr | −6.3%/yr | 5.3 | 0% | 500 in 2030+1.4%/yr |
| Vermont | 10 | 413+2.4%/yr | +2.4%/yr | 3.7 | 0% | 710 in 2030+9.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| EP ablation | 11 | 595+16%/yr | +16%/yr | 2.30.7× | 0% | 1,590 in 2030+18%/yr |
| LAA occlusion & loop recorders | 16 | 537+13%/yr | +13%/yr | 2.10.7× | 11% | 1,450 in 2030+18%/yr |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with New York
Boston Scientific leads with 52% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 7 companies reported engagement with New Hampshire’s surgeons worth $37K in consulting, speaking, meals and travel tied to these products, about $2,080 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.